Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Professor Yuwen Zhou: CAPCET Study Demonstrates a More Effective and Cost-Efficient First-Line Strategy for Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer

    Professor Yuwen Zhou will present the CAPCET study, which focuses on first-line treatment for patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer. By comparing modified CAPOX plus cetuximab with the conventional mFOLFOX6-based regimen, the study demonstrated significant therapeutic advantages. The results showed superior progression-free survival (PFS), overall survival (OS), and objective response rate (ORR), while…

    2026.07.10
  • Professor Haihong Wang: UNION TNT Study Highlights the Potential of Precision Combination Therapy for HER2-Expressing Locally Advanced Rectal Cancer

    Professor Haihong Wang will present the UNION TNT study, which explores short-course radiotherapy combined with disitamab vedotin and immunochemotherapy for patients with HER2-expressing locally advanced rectal cancer. Preliminary findings demonstrate remarkable clinical benefit, with a pathological complete response (pCR) rate of 75% among patients who underwent surgery, while several additional patients achieved clinical complete response…

    2026.07.10
  • Professor Yi Yi Yu: Building a High-Quality IIT Research System at Zhongshan Hospital

    This presentation provided an in-depth overview of Zhongshan Hospital’s investigator-initiated trial (IIT) research system, highlighting its practical experience in infrastructure development, digital platforms, and talent cultivation. Through the implementation of the CREMS management platform, a dual electronic data capture (EDC) system, and the institutional innovation known as the “Zhongshan Ten Measures,” the hospital has established…

    2026.07.10
  • Pujiang Prostate Cancer Summit | Professor Jianming Guo: Breaking Through CRPC Resistance and Why Cytoreductive Surgery for Oligometastatic Disease Is Emerging as the Next Frontier

    The 2026 Pujiang Prostate Cancer Summit was successfully held in Shanghai on June 26–27. Hosted by the Shanghai Anti-Cancer Association and organized by Fudan University Shanghai Cancer Center, the meeting brought together leading experts through keynote lectures, multidisciplinary (MDT) discussions, and live surgical demonstrations to highlight the latest advances in prostate cancer management. Among the…

    2026.07.09
  • Pujiang Prostate Cancer Summit | Professor Dingwei Ye: Expanding Early Screening, Standardizing Care, and Advancing Clinical Research—Three Pillars to Narrow China’s Prostate Cancer Survival Gap

    The 2026 Pujiang Prostate Cancer Summit was held in Shanghai on June 26–27 under the theme “Standardization, Precision, Chinese Innovation, and Global Collaboration.” The meeting brought together leading experts in genitourinary oncology to showcase the latest advances in standardized prostate cancer management and innovative treatment strategies.

    2026.07.09
  • Clear Horizons, Comprehensive Urologic Care | Professor Xin Yao: ADT Remains the Cornerstone of Prostate Cancer Management, While LHRH Antagonists Deliver Both Clinical Efficacy and Quality of Life

    In this edition of Clear Horizons, Comprehensive Urologic Care, Professor Xin Yao from Tianjin Medical University Cancer Institute and Hospital discusses the mechanistic and clinical differences between LHRH agonists and antagonists, as well as practical strategies for managing ADT-related adverse events to maximize both treatment efficacy and patient quality of life.

    2026.07.09
  • APPLE 2026 | Prof. Stephen L. Chan: The Art and Science of Conversion Therapy in Cholangiocarcinoma 

    Cholangiocarcinoma is characterized by its high malignancy, with the majority of patients presenting with unresectable disease at initial diagnosis. In recent years, conversion therapy—which utilizes systemic treatment to downsize tumors—has emerged as a pivotal, offering select patients a pathway to curative-intent resection. However, striking the right balance between therapeutic efficacy and overtreatment remains a significant…

    2026.07.07
  • APACC 2026 | Prof. Jason Ong: Tackling PrEP Accessibility Challenges and Exploring AI-Driven New Pathways for STI Prevention and Control 

    The 2026 Asia-Pacific AIDS and Co-infections Conference (APACC 2026) was successfully held in Tokyo, Japan. Focusing on cutting-edge practices and technological innovations in the prevention and control of HIV and sexually transmitted infections, the conference gathered global experts in the field to explore pathways for optimizing public health services. Our journal specially invited Professor Jason…

    2026.07.06
«previous next»
Recent Posts
  • Nature Reviews | The International Chinese Young Scholars Alliance for the Study of the Liver Facilitates Global Collaboration
  • ESMO 2026丨Looking Ahead: A Quick Review of 26 Chinese Hematologic Oncology Studies Featured at ESMO
  • ESMO Experts’ Perspectives丨Professor Chengcheng Fu: MRD Monitoring May Enable “Selective Treatment Discontinuation” in Multiple Myeloma
  • ESMO Experts’ Perspectives丨Professor Wenbin Qian: Building a “Tumor Ecosystem-Centered” CAR-T System
  • Professor Xingkang Jiang and Professor Gang Song Interpret: Prostate Biopsy Enters the Era of “Precision and Standardization” — ProBIOPSY International Consensus Published, with 34 Leading Experts Establishing Key Standards
Recent Comments
    Archives
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top